Aduro Biotech’s (ADRO) Buy Rating Reaffirmed at Roth Capital
Other equities research analysts have also issued reports about the stock. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a buy rating in a report on Monday, October 24th. Leerink Swann set a $14.00 target price on shares of Aduro Biotech and gave the stock a buy rating in a report on Monday, October 24th. Finally, FBR & Co restated a buy rating on shares of Aduro Biotech in a research note on Tuesday, November 22nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Hold and an average price target of $19.60.
Aduro Biotech (NASDAQ:ADRO) opened at 11.40 on Friday. The stock’s market capitalization is $765.87 million. Aduro Biotech has a 52 week low of $7.26 and a 52 week high of $34.95. The company has a 50 day moving average of $12.58 and a 200 day moving average of $12.98.
Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Wednesday, November 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.09. The firm earned $3.79 million during the quarter, compared to analysts’ expectations of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. The company’s revenue was down 79.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.01 earnings per share. Equities analysts expect that Aduro Biotech will post ($1.34) EPS for the current fiscal year.
WARNING: “Aduro Biotech’s (ADRO) Buy Rating Reaffirmed at Roth Capital” was first posted by Daily Political and is the propert of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The legal version of this article can be read at http://www.dailypolitical.com/2016/11/30/aduro-biotechs-adro-buy-rating-reaffirmed-at-roth-capital.html.
In other news, Director Ross Haghighat sold 7,088 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $15.50, for a total transaction of $109,864.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas W. Dubensky sold 25,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $12.68, for a total value of $317,000.00. Following the transaction, the insider now owns 55,424 shares of the company’s stock, valued at $702,776.32. The disclosure for this sale can be found here. Insiders own 6.50% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ADRO. Vanguard Group Inc. increased its position in Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock worth $20,300,000 after buying an additional 237,924 shares in the last quarter. BlackRock Fund Advisors increased its position in Aduro Biotech by 5.2% in the third quarter. BlackRock Fund Advisors now owns 1,752,256 shares of the company’s stock worth $21,781,000 after buying an additional 87,069 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Aduro Biotech by 21.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 621,844 shares of the company’s stock worth $7,730,000 after buying an additional 110,060 shares in the last quarter. State Street Corp increased its position in Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock worth $6,147,000 after buying an additional 382,654 shares in the last quarter. Finally, BVF Inc. IL purchased a new position in Aduro Biotech during the second quarter worth approximately $5,809,000. Hedge funds and other institutional investors own 35.75% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.